Targanta Therapeutics Corporation is a biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings.

The Company is developing its lead antibiotic, oritavancin, in an intravenous (IV) formulation for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Targanta's Marketing Authorization Application (MAA) for oritavancin for the treatment of cSSSI was accepted for review by the European Medicines Agency (EMEA) in June 2008. Targanta submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in February 2008 seeking to commercialize oritavancin for the treatment of cSSSI; In December 2008, FDA issued a Complete Response Letter to Targanta. In the Letter, FDA indicated that they will require Targanta to perform an additional clinical study to demonstrate efficacy and safety of oritavancin for the treatment of cSSSI in order to gain approval.

Targanta's strategy is to develop oritavancin into a leading therapy worldwide for the treatment of serious gram-positive infections, initially for the treatment of cSSSI and subsequently for other indications.

Targanta is also developing a number of antibacterial agents currently in pre-clinical development, including an oral version of oritavancin targeting Clostridium difficile-related conditions.

The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Québec, Canada.

The Company's common stock trades on the Nasdaq under the symbol: TARG

Download Corporate Fact Sheet